USA flag logo/image

An Official Website of the United States Government

VASCULARIZATION OF MANY SOLID TUMORS OCCURS IN VIVO AS A CONSEQUENCE OF THE…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
4723
Program Year/Program:
1986 / SBIR
Agency Tracking Number:
4723
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Angiogen, Inc.
Angiogen, Inc. 4050 Sorrento Valley Blvd, Ste O San Diego, CA 92121 0142
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1986
Title: VASCULARIZATION OF MANY SOLID TUMORS OCCURS IN VIVO AS A CONSEQUENCE OF THE VECTORIAL GROWTH OF HOST CAPILLARY ENDOTHELIAL CELLS ALONG A CONCENTRATION GRADIENT OF TUMOR- PRODUCED, DIFFUSIBLE ANGIOGENESIS FACTOR(S).
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

VASCULARIZATION OF MANY SOLID TUMORS OCCURS IN VIVO AS A CONSEQUENCE OF THE VECTORIAL GROWTH OF HOST CAPILLARY ENDOTHELIAL CELLS ALONG A CONCENTRATION GRADIENT OF TUMOR- PRODUCED, DIFFUSIBLE ANGIOGENESIS FACTOR(S). THE IDENTIFICATION OF ONE OF THESE FACTORS AS "ANGIOGENIC COPPER" RAISES THE POSSIBILITY THAT COPPER CHELATORS CAN FUNCTION AS ANTIANGIOGENIC AGENTS. THE SPECIFIC AIMS OF THIS PHASE I STUDY ARE: (1) TO TEST VARIOUS COPPER CHELATORS FOR POSSIBLE ANTIANGIOGENIC EFFECTS IN THE CHICKENCHORIOALLANTOIC MEMBRANE (CAM) ASSAY; (2) TO EMPLOY AS ANGIOGENIC STIMULATORS IN THIS SYSTEM (A) COPPER-HEPARIN, A POLYPEPTIDE ANGIOGEN DERIVED FROM NERVOUS TISSUES; (B) A LOWMOLECULAR WEIGHT ANGIOGEN DERIVED FROM THE WALKER 256 RAT TUMOR; AND (C) VIABLE TUMOR CELLS FROM THIS SAME SOURCE; (3) TO ESTABLISH, USING IN VITRO METHODS, WHETHER AGENTS ACTIVE IN THE CAM ASSAY ARE INHIBITING VASCULAR ENDOTHELIAL CELL (EC) MIGRATION AND/OR PROLIFERATION OR ARE TOXIC TO EC AND/OR TUMOR CELLS; AND (4) BASED ON THE OUTCOME OF THE STUDIES RELATED TO THE FIRST THREE OBJECTIVES, TO PREPARE HEPARIN-(OR HEPARIN FRAGMENT) LINKED CHELATORS AND EMPLOY THESE NOVEL SUBSTANCES IN ANALOGOUS STUDIES. RESULTS FROM THESE STUDIES SHOULD ALLOW INDENTIFICATION OF NEW ANTI- ANGIOGENIC AGENTS. THESE SUBSTANCES CAN THEN BE SCREENED MORE THOROUGHLY IN A PHASE II STUDY FOR THEIR ANTICANCER PROPERTIES AGAINST VARIOUS TUMORS IN EXPERIMENTAL ANIMALS. THUS, THE ULTIMATE OBJECTIVE OF THESE STUDIES IS TO DEFINE NOVEL ANTIANGIOGENIC AGENTS THAT WILL PROVIDE IMPROVED MEANSFOR CONTROLLING TUMOR GROWTH AND SPREAD.

Principal Investigator:

Allan h fenselau
PRINCIPAL INVESTIGATOR
3016676880

Business Contact:

Small Business Information at Submission:

Angiogen
107 Lakefront Drive Hunt Valley, MD 21030

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No